Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-15T21:48:27.142Z Has data issue: false hasContentIssue false

A hospital-based HTA model to assess the economic and organizational impact of intravenous-to-subcutaneous monoclonal antibody transitions in oncology

Published online by Cambridge University Press:  17 September 2026

Giorgia Zorzetto*
Affiliation:
Department of Translational Oncology and Services, Pharmacy Unit, Veneto Oncology Institute, Padua, ItalyPostgraduate School of Pharmacology and Clinical Toxicology, University of Brescia, Brescia, Italy
Alberto Russi
Affiliation:
Department of Translational Oncology and Services, Pharmacy Unit, Veneto Oncology Institute, Padua, Italy
Alessandro Giuriola
Affiliation:
Management Control Unit, General Directorate, Veneto Institute of Oncology, Padua, Italy
Giuseppe Di Blasio
Affiliation:
Management Control Unit, General Directorate, Veneto Institute of Oncology, Padua, Italy
Sara Lonardi
Affiliation:
Department of Oncology, Unit of Oncology 1, Veneto Institute of Oncology, Padua, Italy
Valentina Guarneri
Affiliation:
Department of Oncology, Unit of Oncology 2, Veneto Institute of Oncology, Padua, ItalyDepartment of Oncological, Surgical, and Gastroenterological Sciences (DISCOG), University of Padua, Padua, Italy
Marco Maruzzo
Affiliation:
Department of Oncology, Unit of Oncology 3, Veneto Institute of Oncology, Padua, Italy
Maria Vittoria Dieci
Affiliation:
Department of Oncology, Unit of Oncology 2, Veneto Institute of Oncology, Padua, ItalyDepartment of Oncological, Surgical, and Gastroenterological Sciences (DISCOG), University of Padua, Padua, Italy
Giulia Pasello
Affiliation:
Department of Oncology, Unit of Oncology 2, Veneto Institute of Oncology, Padua, ItalyDepartment of Oncological, Surgical, and Gastroenterological Sciences (DISCOG), University of Padua, Padua, Italy
Michele Gottardi
Affiliation:
Department of Oncology, Unit of Onco-Hematology, Veneto Institute of Oncology, Padua, Italy
Silvia Cognolato
Affiliation:
Department of Translational Oncology and Services, Pharmacy Unit, Veneto Oncology Institute, Padua, Italy
Nicoletta Rigamonti
Affiliation:
Department of Translational Oncology and Services, Pharmacy Unit, Veneto Oncology Institute, Padua, Italy
Chiara Mioni
Affiliation:
Department of Translational Oncology and Services, Pharmacy Unit, Veneto Oncology Institute, Padua, Italy
Flavio Cazzador
Affiliation:
Department of Translational Oncology and Services, Pharmacy Unit, Veneto Oncology Institute, Padua, Italy
Giulia Badaile
Affiliation:
Department of Translational Oncology and Services, Pharmacy Unit, Veneto Oncology Institute, Padua, Italy
Francesca Pipitone
Affiliation:
Department of Translational Oncology and Services, Pharmacy Unit, Veneto Oncology Institute, Padua, Italy
Daniela Grosso
Affiliation:
Nurses Coordinating Center, Veneto Institute of Oncology, Padua, Italy
Patrizia Simionato
Affiliation:
Management Control Unit, General Directorate, Veneto Institute of Oncology, Padua, Italy
Giovanna Scroccaro
Affiliation:
Regional Pharmaceutical Office, Veneto Region Health Service Administration, Venice, Italy
Marina Coppola
Affiliation:
Department of Translational Oncology and Services, Pharmacy Unit, Veneto Oncology Institute, Padua, Italy
*
Corresponding author: Giorgia Zorzetto; Email: giorgia.zorzetto@iov.veneto.it
Rights & Permissions [Opens in a new window]

Abstract

Objectives

Subcutaneous (SC) formulations of monoclonal antibodies (mAbs) allow faster and less invasive administration than intravenous (IV) routes, with comparable efficacy and safety. Beyond clinical equivalence, SC administration may reduce hospital resource use, improve patient experience, and increase treatment capacity, contributing to the sustainability of oncology care. This study aimed to develop and apply a hospital-based, multidisciplinary model to assess the economic and organizational impact of IV-to-SC transitions in oncology.

Methods

A scenario-based economic and organizational analysis was conducted using real-world institutional data from a high-volume oncology center, collected before price renegotiations, to estimate the budget impact and resource implications of transitioning from intravenous to subcutaneous mAbs. The analysis included drug acquisition, pharmacy preparation, nursing administration, chair occupancy, and staff time, with preparation costs estimated using Time-Driven Activity-Based Costing (TDABC). The model was applied to two mAbs (X and Y); eligible patients were identified through institutional registries, and scenario analyses simulated partial and complete IV-to-SC substitution across clinical settings.

Results

For antibody X, a full transition to SC administration increased annual treatment capacity by ~36 percent, with an additional drug expenditure of €123,354 and an overall budget impact of €66,778. For antibody Y, full SC adoption increased treatment capacity by ~19 percent, with an additional drug expenditure of €42,473 and a total budget impact of €6,671.

Conclusions

SC-related efficiency gains are highly context-dependent and are maximized in settings with latent capacity demand. The proposed hospital-based HTA framework supports evidence-based adoption strategies and informs sustainable pricing and organizational decision making in oncology.

Information

Type
Assessment
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press
Figure 0

Table 1.Scenario analyses and variables considered for IV-to-SC transitionTable 1. long description.

Figure 1

Figure 1.Overall budget impact of direct costs between scenario 1 (100 percent SC in the adjuvant setting) and scenario 2 (IV), showing cost increments and savings across components.Figure 1. long description.

Figure 2

Figure 2.Overall budget impact of direct costs between scenario 1 (100 percent SC in the neoadjuvant setting) and scenario 2 (IV), showing drug cost increases and savings from nursing, pharmacy, and PICC/port avoidance (€3,896.40/year). In calculating the cost savings related to the avoidance of PICC or port placement, a number of 20 out of 40 patients was considered. This is because, according to therapeutic protocols in the neoadjuvant setting, some patients also receive chemotherapy, which implies the need for PICC or port insertion despite administration of the subcutaneous formulation of antibody X.Figure 2. long description.

Figure 3

Figure 3.Overall budget impact of direct costs between scenario 1 (100 percent switch to the subcutaneous formulation in the metastatic setting) and scenario 2 (intravenous formulation), showing drug cost increases and savings from nursing and pharmacy activities (€35,184.94/year).Figure 3. long description.

Figure 4

Figure 4.Budget impact of direct costs between scenario 1 (100 percent SC in metastatic ≥1 L) and scenario 2 (IV), showing drug cost increases and savings, with a net impact of €45,955.84/year.Figure 4. long description.

Supplementary material: File

Zorzetto et al. supplementary material

Zorzetto et al. supplementary material
Download Zorzetto et al. supplementary material(File)
File 572.3 KB